RZLT - NASDAQ
Rezolute, Inc.
$4.00
+14%Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
At a Glance
Live Snapshotrzlt
Cash at Beginning of Period
Last Annual Value
70.40M
3-Year CAGR
20%
5-Year CAGR
43%
10-Year CAGR
28%
Rezolute, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Rezolute, Inc. NASDAQ:RZLT | 70.40M | -22.4% | 47.9% | 29.6% | |
 Tyra Biosciences, Inc. NASDAQ:TYRA | 92.97M | -28.2% | 43.1% | N/A | |
 Geron Corporation NASDAQ:GERN | 80.88M | 12.2% | 51.0% | 14.3% | |
 Kura Oncology, Inc. NASDAQ:KURA | 224.46M | 63.0% | -7.2% | 30.7% | |
 Prime Medicine, Inc. NASDAQ:PRME | 196.54M | -0.8% | 39.7% | N/A | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 99.85M | 1.5% | 17.3% | 18.0% | |
 Savara Inc. NASDAQ:SVRA | 15.13M | -33.8% | -7.9% | -1.0% | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 124.97M | 13.6% | 23.4% | N/A | |
 ProKidney Corp. NASDAQ:PROK | 99.12M | -41.3% | 85.0% | N/A | |
 Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 322.40M | -20.1% | 6.4% | N/A |
Rezolute, Inc. Fair Value Envelope
Related Guides
Continue your RZLT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.